SPBC1105.13c Antibody

What is SPBC1105.13c and why would researchers develop antibodies against it?

SPBC1105.13c is a systematic gene identifier in the fission yeast Schizosaccharomyces pombe genome. Creating antibodies against this protein is valuable for studying its function, localization, expression levels, and interactions with other proteins. S. pombe serves as an excellent model organism for eukaryotic cell biology, and antibodies against specific proteins like SPBC1105.13c enable researchers to investigate fundamental cellular processes including cell cycle regulation, stress responses, and signal transduction pathways.

What are the recommended methods for validating a newly developed SPBC1105.13c antibody?

Proper validation of a SPBC1105.13c antibody should follow the "five pillars" approach described by the International Working Group for Antibody Validation :

• Genetic validation: Use SPBC1105.13c knockout or knockdown S. pombe strains as negative controls to confirm antibody specificity.

• Orthogonal validation: Compare antibody-based detection with an antibody-independent method (e.g., mass spectrometry or RNA-seq data).

• Independent antibody validation: Use multiple antibodies targeting different epitopes of SPBC1105.13c.

• Expression validation: Test the antibody in systems with induced overexpression of SPBC1105.13c.

• Immunoprecipitation-mass spectrometry: Identify proteins captured by the antibody to confirm target specificity.

It's essential to document these validation steps and report all experimental conditions when publishing results.

What controls should be included when using SPBC1105.13c antibodies in S. pombe experiments?

Proper controls include:

• Negative genetic control: SPBC1105.13c deletion strain (if viable) or knockdown cells

• Positive control: Cells overexpressing tagged SPBC1105.13c (e.g., with V5 or GFP tag)

• Loading controls: Detection of housekeeping proteins to normalize expression levels

• Secondary antibody-only control: To detect non-specific binding

• Pre-immune serum control: For polyclonal antibodies

• Isotype control: For monoclonal antibodies

• Cross-species control: Testing in related yeast species to assess specificity

Documentation of these controls is essential for publication and reproducibility of experiments.

What is the optimal sample preparation protocol for detecting SPBC1105.13c in Western blots?

For optimal Western blot detection of SPBC1105.13c in fission yeast:

• Cell lysis: Use glass bead disruption in buffer containing protease inhibitors, phosphatase inhibitors (if studying phosphorylation), and 1% Triton X-100.

• Protein extraction: Centrifuge lysate at 13,000 × g for 15 minutes at 4°C and collect supernatant.

• Protein quantification: Use Bradford or BCA assay to normalize loading.

• Sample preparation: Mix with Laemmli buffer (containing DTT or β-mercaptoethanol) and heat at 95°C for 5 minutes.

• Gel electrophoresis: Use 10-12% SDS-PAGE gels (adjust percentage based on SPBC1105.13c molecular weight).

• Transfer: Use PVDF membrane for optimal protein retention.

• Blocking: 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute SPBC1105.13c antibody in blocking buffer and incubate overnight at 4°C.

• Detection: Use HRP-conjugated secondary antibodies and ECL detection system.

Always include appropriate positive and negative controls as described in question 1.3.

How can I optimize immunofluorescence protocols for SPBC1105.13c localization studies?

For optimal immunofluorescence detection of SPBC1105.13c in fission yeast:

• Fixation: Use 3.7% formaldehyde for 30 minutes at room temperature.

• Cell wall digestion: Treat with 0.5 mg/ml Zymolyase-20T for 30-60 minutes at 37°C to permeabilize the cell wall.

• Permeabilization: Use 1% Triton X-100 in PBS for 5 minutes.

• Blocking: Incubate in 1% BSA in PBS for 1 hour.

• Primary antibody: Apply diluted SPBC1105.13c antibody and incubate overnight at 4°C.

• Secondary antibody: Use fluorescently labeled secondary antibody (Alexa Fluor dyes recommended).

• Nuclear staining: Include DAPI (1 μg/ml) to visualize nuclei.

• Mounting: Mount cells in anti-fade mounting medium.

• Controls: Include cells without primary antibody and SPBC1105.13c knockout cells as controls.

For co-localization studies, select compatible fluorophores and perform sequential staining if using multiple primary antibodies from the same species.

What are the advantages and limitations of using different types of antibodies against SPBC1105.13c?

For SPBC1105.13c research, recombinant antibodies provide the most consistent results over time . When performing long-term studies or comparing results across multiple experiments, the batch-to-batch consistency of recombinant antibodies offers significant advantages despite their higher cost.

How can I characterize the epitope specificity of a SPBC1105.13c antibody?

To characterize epitope specificity:

• Peptide array analysis: Test antibody binding against overlapping peptides spanning the SPBC1105.13c sequence to identify the recognized region.

• Deletion/truncation mutants: Create a series of SPBC1105.13c truncation constructs and test antibody binding to narrow down the epitope region.

• Site-directed mutagenesis: Introduce point mutations in predicted epitope regions to identify critical amino acid residues.

• Competition assays: Use synthetic peptides corresponding to potential epitopes to compete with full-length protein for antibody binding.

• Cross-reactivity testing: Test against related proteins from the same family to assess epitope conservation.

• Hydrogen-deuterium exchange mass spectrometry: For detailed conformational epitope mapping.

Understanding the epitope helps predict potential cross-reactivity issues and informs experimental design when studying protein modifications or interactions that might interfere with antibody binding.

How can I develop isotopically labeled SPBC1105.13c antibodies for advanced structural studies?

For isotopic labeling of antibodies against SPBC1105.13c:

• Expression system selection: Use E. coli-based expression systems for efficient isotope incorporation (>99% incorporation can be achieved) .

• Labeling strategy:

  • For NMR studies: Use 13C-glucose and 13C-celtone in growth media

  • For neutron scattering: Incorporate deuterium (2H) labels

  • For mass spectrometry: Consider 15N labeling

• Fragment-based approach: Express Fab fragments rather than full antibodies for better expression yield in bacterial systems.

• Purification optimization: Use affinity chromatography followed by size exclusion chromatography to obtain pure labeled antibody.

• Validation: Confirm labeling efficiency by mass spectrometry and binding activity by ELISA.

Isotopically labeled antibodies enable detailed structural studies using NMR spectroscopy and can reveal dynamics of antibody-antigen interactions at atomic resolution.

What strategies can resolve contradictory results when using different SPBC1105.13c antibodies?

When different antibodies against SPBC1105.13c yield contradictory results:

• Epitope mapping: Determine if the antibodies recognize different epitopes that might be differentially accessible in various experimental conditions.

• Validation re-assessment: Thoroughly re-validate each antibody using genetic controls and orthogonal methods.

• Post-translational modifications: Investigate if modifications (phosphorylation, methylation, etc.) affect epitope recognition.

• Protein complex formation: Test if protein-protein interactions mask certain epitopes.

• Experimental conditions comparison: Systematically compare fixation methods, detergents, and buffers used.

• Knockout validation: Generate CRISPR-based knockout controls in your specific cell type.

• Corroborating techniques: Use non-antibody techniques (e.g., mass spectrometry, RNA interference phenotypes) to resolve discrepancies.

Document all validation steps thoroughly for publication purposes and maintain consistent experimental conditions when comparing antibodies.

How can I minimize background staining when using SPBC1105.13c antibodies for immunofluorescence in S. pombe?

To reduce background staining:

• Optimize fixation: Test different fixatives (formaldehyde, methanol, glutaraldehyde) and fixation times.

• Improve blocking: Increase BSA concentration (3-5%) or try different blocking agents like normal serum from the secondary antibody species.

• Antibody dilution optimization: Perform titration series to find optimal antibody concentration.

• Pre-absorption: Incubate antibody with SPBC1105.13c knockout cell lysate to remove cross-reactive antibodies.

• Secondary antibody selection: Use highly cross-adsorbed secondary antibodies to reduce species cross-reactivity.

• Washing optimization: Increase number and duration of washes with 0.1% Tween-20 in PBS.

• Autofluorescence reduction: Include quenching steps (e.g., sodium borohydride treatment) if autofluorescence is an issue.

• Compare detergents: Test Triton X-100, Tween-20, and saponin for optimal permeabilization with minimal background.

Always include appropriate negative controls to distinguish specific from non-specific staining.

What are the most effective extraction methods for detecting SPBC1105.13c in different subcellular compartments?

Different extraction methods optimize detection of SPBC1105.13c in various subcellular locations:

For cytoplasmic proteins:

• Use mild detergents (0.1% Triton X-100 or 0.5% NP-40)

• Buffer: 20 mM HEPES pH 7.4, 150 mM NaCl, 1 mM EDTA, protease inhibitors

For nuclear proteins:

• First extract cytoplasmic proteins, then use nuclear extraction buffer

• Buffer: 20 mM HEPES pH 7.9, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 25% glycerol, protease inhibitors

For membrane-bound proteins:

• Use stronger detergents (1% SDS or 1% Triton X-100)

• Buffer: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% detergent, protease inhibitors

For chromatin-associated proteins:

• Perform chromatin fractionation with nuclease treatment

• Use both DNase and RNase to release DNA/RNA-bound proteins

For comprehensive detection, perform sequential extraction and analyze each fraction separately to determine the predominant localization of SPBC1105.13c.

How can I differentiate between specific and non-specific binding in SPBC1105.13c immunoprecipitation experiments?

To distinguish specific from non-specific binding:

• Stringent controls:

  • Use SPBC1105.13c knockout cells as negative control

  • Include isotype control or pre-immune serum IP

  • Perform competitive elution with SPBC1105.13c peptides

• Optimized washing conditions:

  • Test increasing salt concentrations (150-500 mM NaCl)

  • Evaluate different detergents (0.1-1% Triton X-100, NP-40, Tween-20)

  • Include low concentrations of SDS (0.1%) in later washes

• Cross-validation approaches:

  • Confirm interactions with reciprocal IP experiments

  • Use tagged version of SPBC1105.13c (FLAG, HA, GFP) for comparison

  • Validate interactions with orthogonal methods (proximity ligation, FRET)

• Mass spectrometry analysis:

  • Compare proteins identified in experimental vs. control IPs

  • Apply statistical cutoffs (e.g., >2-fold enrichment, p<0.05)

  • Look for known interactors of SPBC1105.13c functional partners

• Data analysis:

  • Create comprehensive lists of common contaminants in your system

  • Use CRAPome or similar databases to filter out common non-specific binders

  • Apply quantitative approaches (SILAC, TMT) to differentiate true interactions

How can I use SPBC1105.13c antibodies to study protein-protein interactions in fission yeast?

Several approaches can be used:

• Co-immunoprecipitation (Co-IP):

  • Use the SPBC1105.13c antibody to pull down the protein complex

  • Analyze interacting partners by Western blot or mass spectrometry

  • Confirm with reciprocal IP using antibodies against putative partners

• Proximity-dependent labeling:

  • Create SPBC1105.13c fusion with BioID or APEX2

  • Identify proximal proteins through biotinylation and streptavidin pulldown

  • Validate interactions with Co-IP using SPBC1105.13c antibodies

• Chromatin immunoprecipitation (ChIP):

  • If SPBC1105.13c is a DNA-binding protein, use ChIP to identify DNA targets

  • Combine with RNA-seq to correlate binding with transcriptional changes

  • Use sequential ChIP to identify co-binding partners

• Förster resonance energy transfer (FRET):

  • Use fluorescently labeled SPBC1105.13c antibody fragments

  • Combine with antibodies against putative partners

  • Measure energy transfer to confirm close proximity

• Protein complementation assays:

  • Split-fluorescent protein fusions to validate interactions identified with antibodies

Carefully optimize conditions for each technique and include appropriate controls to ensure specificity of detected interactions.

What considerations are important when using SPBC1105.13c antibodies for quantitative proteomics?

For quantitative proteomics applications:

• Antibody characterization:

  • Ensure complete validation of antibody specificity

  • Determine linear detection range for quantitative applications

  • Assess batch-to-batch variability if using multiple antibody lots

• Sample preparation:

  • Standardize lysis conditions and protein extraction protocols

  • Use consistent sample processing for all experimental groups

  • Include spike-in standards for normalization

• Experimental design:

  • Include biological and technical replicates (minimum n=3 for each)

  • Randomize sample processing order to minimize batch effects

  • Include appropriate positive and negative controls

• Data acquisition and analysis:

  • Use multiple peptides per protein for reliable quantification

  • Apply appropriate statistical tests for comparisons

  • Consider using isotope-labeled standards for absolute quantification

• Reporting standards:

  • Document all antibody information (source, catalog number, lot, dilution)

  • Report all sample preparation and acquisition parameters

  • Share raw data in public repositories for reproducibility

Using recombinant antibodies is highly recommended for quantitative studies due to their consistency across experiments .

How can I effectively use SPBC1105.13c antibodies in ChIP-seq experiments?

For optimal ChIP-seq results with SPBC1105.13c antibodies:

• Antibody selection and validation:

  • Ensure the antibody works specifically in ChIP applications

  • Validate with known binding targets using ChIP-qPCR

  • Test different antibody concentrations to optimize signal-to-noise ratio

• Crosslinking optimization:

  • Test different formaldehyde concentrations (0.5-1.5%)

  • Optimize crosslinking times (5-20 minutes)

  • Consider dual crosslinking with additional agents for challenging interactions

• Chromatin preparation:

  • Optimize sonication conditions to achieve 200-500 bp fragments

  • Verify fragment size by agarose gel electrophoresis

  • Pre-clear chromatin to reduce non-specific binding

• IP conditions:

  • Titrate antibody amount (2-10 μg per reaction)

  • Optimize incubation time (overnight at 4°C recommended)

  • Include appropriate controls (IgG control, input sample)

• Bioinformatic analysis:

  • Use appropriate peak calling algorithms

  • Perform motif enrichment analysis

  • Integrate with transcriptomic data to connect binding with function

• Validation:

  • Confirm key targets with independent ChIP-qPCR

  • Use CRISPR-mediated knockout of SPBC1105.13c as negative control

  • Compare with published datasets if available

Detailed documentation of all procedures is essential for reproducibility and publication.